The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

The study was a three-arm, active-control, multi-centre, parallel group study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals
• Treatments: Leuprolide

Criteria

Main Inclusion Criteria:

• Patients, aged 18 years or over, with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.

• Baseline testosterone >1.5 ng/mL.

• Life expectancy of at least 12 months.